Association of creatinine-adjusted urine concentration Saxagliptin - PowerPoint PPT Presentation

Association of creatinine-adjusted urine concentration Saxagliptin and Cardiovascular Outcomes in Patients or activity of RAS pathway components with DKD in with Type 2 Diabetes Mellitus people with type 1 diabetes No DKD DKD OR (95%CI) p-value Median (IQR) Median (IQR) 9.6 x 10 -10 Angiotensinogen/Cr (µg/g) 15 (8, 24) 170 (18, 597) 2.2 (1.2, 3.3) 2.3 x 10 -14 Cathepsin D/Cr (µg/g) 31 (22, 46) 147 (85, 219) 6.5 (3.5, 14.6) ACE/Cr (µg/g) 0.8 (0.4, 1.4) 1.4 (0.9, 2.5) 2.2 (1.4, 3.9) 3.8 x 10 -4 ACE activity/Cr 1.6 (1.0, 2.1) 1.0 (0.8, 1.2) 0.3 (0.1, 0.6) 4.6 x 10 -4 (10 9 RFU/hr/g) ACE2/Cr (µg/g) 2.7 (1.7, 4.2) 4.1 (1.6, 5.7) 1.1 (0.8, 1.7) 0.54 ACE2 activity/Cr 0.3 (0.1, 0.9) 0.4 (0.2, 0.9) 1.2 (1.0, 1.4) 0.03 (10 6 RFU/hr/g) APA activity/Cr 22 (4, 89) 40 (11, 210) 1.2 (1.0, 1.3) 0.05 (10 6 RFU/hr/g) People with no DKD had eGFR >90 ml/min/1.73m 2 and ACR <300 mg/g after >30 years of type 1 diabetes. Those with DKD had either an ACR >300 mg/g or both eGFR <60 ml/min/1.73m 2 and ACR >30 mg/g. Wysocki J et al, Am J Physiol Renal Physiol May 3, 2017 (Epub ahead of print)

Association of urine concentration or activity of RAS Saxagliptin and Cardiovascular Outcomes in Patients pathway components with DKD in with Type 2 Diabetes Mellitus people with type 1 diabetes OR (95%CI) p-value Age, years 0.9 (0.8, 1.0) 0.16 Non-white 1.8 (0.2, 14.8) 0.054 Female 0.5 (0.1, 2.6) 0.41 Diabetes duration, years 1.0 (0.9, 1.0) 0.31 Angiotensinogen/Cr (µg/g) 1.5 (0.9, 2.8) 0.11 1.5 x 10 -6 Cathepsin D/Cr (µg/g) 6.5 (2.7, 22.4) ACE activity/Cr (10 6 RFU/hr/g) 0.2 (0.1, 0.6) 0.003 ACE2 activity/Cr (10 3 RFU/hr/g) 1.0 (0.8, 1.4) 0.98 APA activity/Cr (10 6 RFU/hr/g) 0.9 (0.7, 1.2) 0.36 People with no DKD had eGFR >90 ml/min/1.73m 2 and ACR <300 mg/g after >30 years of type 1 diabetes. Those with DKD had either an ACR >300 mg/g or both eGFR <60 ml/min/1.73m 2 and ACR >30 mg/g. Wysocki J et al, Am J Physiol Renal Physiol May 3, 2017 (Epub ahead of print)

RAS pathway status in experimental DKD, based on Saxagliptin and Cardiovascular Outcomes in Patients urine concentration and enzymatic activity of with Type 2 Diabetes Mellitus RAS components Wysocki J et al, Am J Physiol Renal Physiol May 3, 2017 (Epub ahead of print)

RAS pathway status in human DKD, based on urine Saxagliptin and Cardiovascular Outcomes in Patients concentration and enzymatic activity of with Type 2 Diabetes Mellitus RAS components Wysocki J et al, Am J Physiol Renal Physiol May 3, 2017 (Epub ahead of print)